<DOC>
	<DOCNO>NCT02599688</DOCNO>
	<brief_summary>This open-label , observational extension patient receive POLAT-001 LipoLat-CS202 .</brief_summary>
	<brief_title>Open Label Extension LipoLat-CS202</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<criteria>Inclusion criterion 1 . Successful completion 3 month participation Study LipoLatCS202 . 2 . Treatment POLAT001 Study LipoLatCS202 . 3 . Able willing give sign informed consent follow study instruction . Exclusion criterion Excluded study individual follow characteristic : 1 . The development , study LipoLatCS202 , exclusion criterion study ( e.g. , concomitant medication comorbid disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>